Khiron views the election of Mr. Duque as a positive development for the nation and the people of Colombia, in general, as well as for the developing medical cannabis industry in Colombia, in particular.
“Khiron applauds the election of Mr. Duque and is fully aligned with the new government’s stated social and economic positions. In particular, we support the government elect’s commitment to maintaining and improving upon a regulatory environment that enables and attracts foreign investment to create sustainable and secure job opportunities in emerging industries and to provide new health treatment alternatives for Colombians,” said Alvaro Torres, CEO of Khiron.
Core elements of Mr. Duque’s agenda include:
- Ensuring rating agencies maintain and increase the investment grade rating of Colombia.
- Deepening of capital markets and banking relationships to accelerate growth.
- Generating greater gross domestic product growth.
- Simplifying Colombia’s tax systems.
- Introducing new measures to provide increased healthcare alternatives for Colombians.
- Ensuring fiscal accountability and transparency.
- Firming Colombia’s stance on the illegal trade of narcotics.
“This landmark election result provides for the continuation of the important economic and social reforms that have helped Colombia gain standing and respect on global trade in recent years. We believe it will lead to the creation of jobs and sustainable growth in a stable economic environment for many years to come.” Says Torres.
About Khiron Life Sciences Corp.
Khiron is a Canadian integrated medical cannabis company with its core operations in Colombia, and is fully licenced in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. Khiron combines leading international scientific expertise, agricultural advantages, and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America.
Further information on Khiron Life Sciences can be found at www.khiron.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Filing Statement which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.